Study for the Sensitivity of Gilteritinib in Acute Myeloid Leukemia

Study for the Sensitivity of Gilteritinib in Acute Myeloid Leukemia - Study for the Sensitivity of Gilteritinib in Acute Myeloid Leukemia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039778

Enrollment

Registered

2020-03-16

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Subject is relapsed / refractory AML. 2.Subject is positive for FLT3 gene mutation and scheduled to receive gilteritinib. 3.Subject with written consent to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Subject has difficulty to give written consent. 2. Subject is judged to be inappropriate for this study by the investigator.

Design outcomes

Primary

Measure	Time frame
Correlation between plasma inhibitory activity (PIA) and best response during the treatment in the patients who are treated with gilteritinib	—

Secondary

Measure	Time frame
1. Relationship between the efficacy of gilteritinib and gene mutations 2.Correlation between the efficacy of gilteritinib and minimal residual disease 3.Relationship between PIA and gilteritinib blood levels	—

Countries

Japan

Contacts

Public ContactYuichi Ishikawa

Nagoya University Graduate School of Medicine Department of Hematology and Oncology

yishikaw@med.nagoya-u.ac.jp052-744-2145

Outcome results